Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $6.3 million.

  • Haemonetics' Capital Expenditures fell 2570.79% to $6.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $30.8 million, marking a year-over-year increase of 145.78%. This contributed to the annual value of $39.3 million for FY2025, which is 302.43% up from last year.
  • Latest data reveals that Haemonetics reported Capital Expenditures of $6.3 million as of Q4 2025, which was down 2570.79% from $5.0 million recorded in Q3 2025.
  • Haemonetics' Capital Expenditures' 5-year high stood at $93.1 million during Q2 2023, with a 5-year trough of $3.8 million in Q2 2025.
  • In the last 5 years, Haemonetics' Capital Expenditures had a median value of $12.8 million in 2021 and averaged $19.6 million.
  • In the last 5 years, Haemonetics' Capital Expenditures skyrocketed by 22665.42% in 2022 and then crashed by 9281.61% in 2024.
  • Haemonetics' Capital Expenditures (Quarter) stood at $20.8 million in 2021, then fell by 19.05% to $16.8 million in 2022, then decreased by 13.07% to $14.6 million in 2023, then tumbled by 41.65% to $8.5 million in 2024, then fell by 25.71% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q4 2025, $5.0 million for Q3 2025, and $3.8 million during Q2 2025.